Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.45
(0.41%)
HKD 2.45
(0.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 17.28 Million CNY | -86.15% |
| 2022 | 124.81 Million CNY | 299.23% |
| 2021 | 31.26 Million CNY | 58.77% |
| 2020 | 19.69 Million CNY | -87.3% |
| 2019 | 155.09 Million CNY | 3.4% |
| 2018 | 150 Million CNY | 7.14% |
| 2017 | 140 Million CNY | 16.67% |
| 2016 | 120 Million CNY | -4.0% |
| 2015 | 125 Million CNY | 400.0% |
| 2014 | 25 Million CNY | -37.5% |
| 2013 | 40 Million CNY | -68.38% |
| 2012 | 126.49 Million CNY | 61.53% |
| 2011 | 78.31 Million CNY | 7.3% |
| 2010 | 72.98 Million CNY | 12.88% |
| 2009 | 64.65 Million CNY | 22.79% |
| 2008 | 52.65 Million CNY | 23.45% |
| 2007 | 42.65 Million CNY | 113.25% |
| 2006 | 20 Million CNY | 0.0% |
| 2005 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 9.86 Million CNY | -42.89% |
| 2024 Q2 | 12.22 Million CNY | 23.85% |
| 2023 FY | 17.28 Million CNY | -86.15% |
| 2023 Q2 | 119.29 Million CNY | 4.22% |
| 2023 Q1 | 114.46 Million CNY | -8.29% |
| 2023 Q3 | 110.42 Million CNY | -7.44% |
| 2023 Q4 | 17.28 Million CNY | -84.35% |
| 2022 Q4 | 124.81 Million CNY | 623.0% |
| 2022 FY | 124.81 Million CNY | 299.23% |
| 2022 Q3 | 17.26 Million CNY | -39.68% |
| 2022 Q2 | 28.62 Million CNY | 37.21% |
| 2022 Q1 | 20.86 Million CNY | -33.28% |
| 2021 Q3 | 24.57 Million CNY | 8.08% |
| 2021 Q2 | 22.73 Million CNY | 86.84% |
| 2021 FY | 31.26 Million CNY | 58.77% |
| 2021 Q1 | 12.16 Million CNY | -38.2% |
| 2021 Q4 | 31.26 Million CNY | 27.22% |
| 2020 Q1 | 205.25 Million CNY | 32.34% |
| 2020 Q2 | 165.4 Million CNY | -19.42% |
| 2020 Q3 | 116.23 Million CNY | -29.73% |
| 2020 Q4 | 19.69 Million CNY | -83.06% |
| 2020 FY | 19.69 Million CNY | -87.3% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 148.34 Million CNY | 0.0% |
| 2019 Q4 | 155.09 Million CNY | 0.0% |
| 2019 FY | 155.09 Million CNY | 3.4% |
| 2018 Q1 | 150 Million CNY | 7.14% |
| 2018 Q4 | 150 Million CNY | 0.0% |
| 2018 Q3 | 150 Million CNY | 0.0% |
| 2018 FY | 150 Million CNY | 7.14% |
| 2018 Q2 | 150 Million CNY | 0.0% |
| 2017 FY | 140 Million CNY | 16.67% |
| 2017 Q3 | 140 Million CNY | -12.5% |
| 2017 Q2 | 160 Million CNY | 0.0% |
| 2017 Q1 | 160 Million CNY | 33.33% |
| 2017 Q4 | 140 Million CNY | 0.0% |
| 2016 Q2 | 90 Million CNY | 0.0% |
| 2016 Q4 | 120 Million CNY | 0.0% |
| 2016 FY | 120 Million CNY | -4.0% |
| 2016 Q1 | 90 Million CNY | -28.0% |
| 2016 Q3 | 120 Million CNY | 33.33% |
| 2015 Q3 | 125 Million CNY | -20.53% |
| 2015 FY | 125 Million CNY | 400.0% |
| 2015 Q2 | 157.3 Million CNY | 0.0% |
| 2015 Q4 | 125 Million CNY | 0.0% |
| 2015 Q1 | 157.3 Million CNY | 529.2% |
| 2014 FY | 25 Million CNY | -37.5% |
| 2014 Q4 | 25 Million CNY | 0.0% |
| 2014 Q3 | 25 Million CNY | 0.0% |
| 2014 Q2 | 25 Million CNY | 0.0% |
| 2014 Q1 | 25 Million CNY | -37.5% |
| 2013 Q2 | 80 Million CNY | 0.0% |
| 2013 Q4 | 40 Million CNY | 0.0% |
| 2013 FY | 40 Million CNY | -68.38% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 Q2 | 112.15 Million CNY | 0.0% |
| 2012 FY | 126.49 Million CNY | 61.53% |
| 2012 Q4 | 126.49 Million CNY | 0.0% |
| 2011 FY | 78.31 Million CNY | 7.3% |
| 2011 Q2 | 102.98 Million CNY | 0.0% |
| 2011 Q4 | 78.31 Million CNY | 0.0% |
| 2010 Q2 | 33.65 Million CNY | 0.0% |
| 2010 FY | 72.98 Million CNY | 12.88% |
| 2010 Q4 | 72.98 Million CNY | 0.0% |
| 2009 FY | 64.65 Million CNY | 22.79% |
| 2008 FY | 52.65 Million CNY | 23.45% |
| 2007 FY | 42.65 Million CNY | 113.25% |
| 2006 FY | 20 Million CNY | 0.0% |
| 2005 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -153.77% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 99.492% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 85.648% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 96.251% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -3448.614% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 91.534% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 94.122% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 94.823% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 95.932% |
| SSY Group Limited | 3.37 Billion HKD | 99.488% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 87.046% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 97.694% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.98% |